Skip to main content

CDX-1140 + CDX-301 + Liposomal Doxorubicin

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

  • RegistryNCT05029999
  • PhasePhase 1
  • StatusRecruiting
  • ConditionMetastatic HER2-Negative Breast Cancer
  • SponsorUniversity of Texas Southwestern Medical Center
How CDX-1140 + CDX-301 + PLD works1 min

The drug

What is being tested.

CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.

CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.

The immunotherapy drugs CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment PLD work by kickstarting the immune response against cancer cells. CDX-301 increases the antigen presenting immune cells needed to kickstart the immune response, CDX-1140 activates these cells, and chemotherapy helps release antigens from the cancer cells to train these antigen presenting immune cells to recognize the cancer for the immune system to attack it.

The study

How the trial runs.

This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer, and to determine a safe dose and treatment schedule of the three drugs.

This research study will also test how your immune system responds to these treatments alone and in combination.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Unresectable Stage III or Stage IV HER2 negative breast cancer (either triple negative or hormone receptor positive)
  • Triple negative breast cancer for this study is defined as estrogen receptor <10%, progesterone receptor <10% by immunohistochemistry, and HER2- negative by Herceptest (0 or 1+) or not amplified by in situ hybridization as per routine clinical testing.
  • Hormone receptor positive breast cancer for this study is defined as either estrogen receptor ≥10% or progesterone receptor ≥10% by immunohistochemistry, and HER2- negative by Herceptest (0 or 1+) or not amplified by in situ hybridization as per routine clinical testing.
  • Age 18 years or older
  • Performance status ECOG 0-2
  • Life expectancy ≥ 12 weeks

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.

Not sure whether you would qualify?

Would this trial apply to me?

7-day free trial, then $9 a month. Cancel anytime.